Injectsense
A Serious Unmet Need -- with Significant Quality-of-Life Implications They live in a new era where they are constantly connected. They receive remote updates on almost all information critical to their lives and lifestyle, and they have the ability to monitor event status and to predict and plan for change. Yet in the medical field, a physician treating a progressive disease often has no choice but to be reactive -- often with harmful results. Critical data on patient disease state is collected infrequently during sporadic office visits, yielding only a single data point to interpret past trends and assess long-term risk. Unlike their personal updates, continously available via sensors, GIS, and smart phone connectivity, there is no continuous stream of physiological measurement data from patients that can allow physicians to track and anticipate changes in disease status. The medical team cannot see how patient activity may be affecting disease indicators, and they can't see whether patients are even complying with drug therapy. The end result? More patient visits to the ER and doctor's office -- often when physiological damage has already been done. Injectsense: A New Paradigm for Therapy Management Injectsense enables tracking of progressive disease indicators and improved therapy management by providing continuous, clinically actionable information through an injectable ultra-miniature sensor coupled with a secure digital health platform. Their sensor, which can be delivered during a doctor's office visit, transforms the care model by enabling medical teams to track the disease at the pace of its evolution, whether months or years, receive early warning signs and provide preventive therapy. The configurable-on-demand sensor monitors patients 24/7, requires no patient lifestyle changes and reduces the need for medical office visits. More significantly, it allows physicians to establish an individual patient baseline for comparison, to receive data quickly at any time of day, to see histories and hourly dynamic disease state before irreversible damage is done, and to increase the effectiveness of drug therapy by tracking the effects of pharmaceuticals on key indicators over time.
A Serious Unmet Need -- with Significant Quality-of-Life Implications They live in a new era where they are constantly connected. They receive remote updates on almost all information critical to their lives and lifestyle, and they have the ability to monitor event status and to predict and plan for change. Yet in the medical field, a physician treating a progressive disease often has no choice but to be reactive -- often with harmful results. Critical data on patient disease state is collected infrequently during sporadic office visits, yielding only a single data point to interpret past trends and assess long-term risk. Unlike their personal updates, continously available via sensors, GIS, and smart phone connectivity, there is no continuous stream of physiological measurement data from patients that can allow physicians to track and anticipate changes in disease status. The medical team cannot see how patient activity may be affecting disease indicators, and they can't see whether patients are even complying with drug therapy. The end result? More patient visits to the ER and doctor's office -- often when physiological damage has already been done. Injectsense: A New Paradigm for Therapy Management Injectsense enables tracking of progressive disease indicators and improved therapy management by providing continuous, clinically actionable information through an injectable ultra-miniature sensor coupled with a secure digital health platform. Their sensor, which can be delivered during a doctor's office visit, transforms the care model by enabling medical teams to track the disease at the pace of its evolution, whether months or years, receive early warning signs and provide preventive therapy. The configurable-on-demand sensor monitors patients 24/7, requires no patient lifestyle changes and reduces the need for medical office visits. More significantly, it allows physicians to establish an individual patient baseline for comparison, to receive data quickly at any time of day, to see histories and hourly dynamic disease state before irreversible damage is done, and to increase the effectiveness of drug therapy by tracking the effects of pharmaceuticals on key indicators over time.
Injectsense has raised $4.2M across 2 rounds. Its most recent round was a Series Unknown of $2.5M in Nov 2023. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Injectsense is featured in
Similar companies
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.
Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Nuvectis Pharma is a biopharmaceutical company focused on creating new targeted treatments for cancer. The company is headed by a team of experienced industry professionals who have successfully developed drugs and navigated clinical and regulatory processes. Through our expertise in selecting targets, profiling drugs, and executing clinical trials, we are working to develop a range of new products for cancer treatment.
Andon Bio is a biotechnology company that measures genetic parameters such as tRNAs predict and analyze protein expression.
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
Siren Biotechnology combines AAV gene therapy and cytokine immunotherapy into a new method for treating cancer. By merging these two innovative technologies, Siren Biotechnology has created a unique approach that overcomes challenges and revolutionizes the way tumor cells are targeted and the immune response to tumors is enhanced.
Decoy Therapeutics is a preclinical stage biotech company building a pandemic preparedness drug development platform using AI design of peptide ‘decoys’ that directly interfere with viral replication machinery.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.